Keywords

Breast cancer survivorship, Cancer-related symptoms, Cognitive impairment, Fatigue, Latent Profile Analysis, Quality of Life, Sleep disturbance

 

Authors

  1. Whisenant, Meagan S. PhD, APRN
  2. Williams, Loretta A. PhD, APRN
  3. Mendoza, Tito PhD, MS, Med
  4. Cleeland, Charles PhD
  5. Chen, Tsun-Hsuan PhD
  6. Fisch, Michael J. MD, MPH, FACP, FAAHPM, FASCO
  7. Shi, Quiling MD, PhD, MSc

Abstract

Background: While women diagnosed with breast cancer have increased survival when compared with other cancers, survivorship may include residual symptom burden from treatment and continuing endocrine therapies.

 

Objective: The objective of this study was to identify subgroups of breast cancer survivors experiencing similar symptom severity.

 

Methods: Participants were 498 women with breast cancer, not on active treatment. Symptom severity was self-reported using the MD Anderson Symptom Inventory. Target symptoms were included in a latent profile analysis. Factors related to subgroup membership and differences in quality of life (QOL) and functioning were explored using logistic regression.

 

Results: Mean age was 60.11 (SD, 11.32) years, 86.1% were white, and 79.1% were receiving endocrine therapy. Target symptoms included fatigue (reported at >=5 by 22.8% of women), sleep disturbance (24.8%), and trouble remembering (17.2%). Two subgroups were identified: low symptom severity (77.0% of women) and high (23.0%). Older women (odds ratio [OR], 0.971; 95% confidence interval [CI], 0.952-0.989) and employed women (OR, 0.621; 95% CI, 0404-0.956) were less likely to be in the high subgroup; women with poorer performance status (OR, 1.653; 95% CI, 1.188-2.299) were more likely to be in the high subgroup. Women in the high subgroup reported lower QOL (P = .000) and greater interference with functioning (P = .000).

 

Conclusions: Two subgroups of women with distinct symptom severity were identified.

 

Implications for Practice: Identification of women at risk for high symptoms during survivorship may allow clinicians to intensify their approach to symptom management, thereby mitigating poor outcomes and impairments in QOL.